CTLA4 and prostate neoplasm: Bishop et al. [91] showed variations in PD-L1 expression in prostate tumors, suggesting that the levels of immune checkpoint molecule expression vary in different stages of PC progression and our data of PD-L1 and CTLA4 mRNA expression confirmed this mechanism.